| European Case Law Identifier: | ECLI:EP:BA:2014:T083311.20140408 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 08 April 2014 | ||||||||
| Case number: | T 0833/11 | ||||||||
| Application number: | 01953272.0 | ||||||||
| IPC class: | C07J 31/00 C07J 17/00 A61K 31/58 A61P 5/44 A61P 11/06 A61P 11/08 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | D | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | 6.alpha.,9.alpha.-Difluoro-17.alpha.-(2-furanylcarbonyl)-oxy-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4-diene-17.beta.-carbothioic acid S-fluoromethyl ester as an anti-inflammatory agent | ||||||||
| Applicant name: | GLAXO GROUP LIMITED | ||||||||
| Opponent name: | NORTON HEALTHCARE LIMITED | ||||||||
| Board: | 3.3.01 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Main request, allowable Sufficiency (yes) Novelty (yes), specific ester Inventive step (yes), choice of closest prior art Admission of late-filed document (no) Apportionment of costs (no) Remittal (no) |
||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t110833eu1.html
Date retrieved: 17 May 2021